当前蛋白身份:P24864 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1W98 The structural basis of CDK2 activation by cyclin E 提交 2004-10-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa) 片段:FRAGMENT DERIVED FROM ELASTASE CLEAVAGE, RESIDUES 96-378
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.5;PCDK2/CYCLIN E (6-8 MG/ML), 1 MM AMPPNP, 10-15% PEG3350, 0.2 M SODIUM CITRATE PH7.5, pH 7.50
分辨率 2.15 Å R-free 0.246
5L2W The X-ray co-crystal structure of human CDK2/CyclinE and Dinaciclib. 提交 2016-08-02 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 81–363(283 aa) 片段:UNP residues 81-363
未记录 1QK 3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)methyl]-1-hydroxypyridinium × 1 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;286.15 K;PEG20K, 180mM Mg(HCO2)2, 0.1M MES pH 6.0
分辨率 2.80 Å R-free 0.246
7KJS Crystal structure of CDK2/cyclin E in complex with PF-06873600 提交 2020-10-26 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 WG1 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6;294.15 K;0.1 M MES pH 6, .18 M magnesium formate, and 9.0 % (w/v) PEG 20000
分辨率 2.19 Å R-free 0.278
7XQK The Crystal Structure of CDK3 and CyclinE1 Complex from Biortus. 提交 2022-05-07 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 SO4 SULFATE ION × 11 GOL GLYCEROL × 3 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;1.6M MgSO4, 0.1M MES pH6.5
分辨率 2.25 Å R-free 0.202
8H4R The Crystal Structure of CDK3 and CyclinE1 Complex with Dinaciclib from Biortus 提交 2022-10-11 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 1QK 3-[({3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl}amino)methyl]-1-hydroxypyridinium × 1 SO4 SULFATE ION × 6 GOL GLYCEROL × 2 MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;1.6M MgSO4, 0.1M MES pH 6.60
分辨率 2.75 Å R-free 0.223
8H6P Complex structure of CDK2/Cyclin E1 and a potent, selective macrocyclic inhibitor 提交 2022-10-18 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 103–373(271 aa) 片段:Residues 103-373
未记录 WZU (7S,10R)-11-oxa-2,4,5,13,17,23-hexaazatetracyclo[17.3.1.1~3,6~.1~7,10~]pentacosa-1(23),3(25),5,19,21-pentaene-12,18-dione × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291.15 K;0.2 M sodium citrate pH 6.5, 10% PEG3350
分辨率 2.44 Å R-free 0.292
8H6T Complex structure of CDK2/Cyclin E1 and a potent, selective small molecule inhibitor 提交 2022-10-18 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 102–373(272 aa) 片段:Residues 103-373
未记录 WZZ (1R,3S)-3-{3-[(pyridin-2-yl)amino]-1H-pyrazol-5-yl}cyclopentyl propan-2-ylcarbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;291.15 K;0.2 M sodium citrate pH 6.5, 10% PEG3350
分辨率 3.00 Å R-free 0.358
8VQ3 CDK2-CyclinE1 in complex with allosteric inhibitor I-198. 提交 2024-01-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1AC4 (8R)-N-[(2S,3R)-3-(cyclohexylmethoxy)-1-(morpholin-4-yl)-1-oxobutan-2-yl]-2-[(1S)-2,2-dimethylcyclopropane-1-carbonyl]-6-(1,3-thiazole-5-carbonyl)-2,6-diazaspiro[3.4]octane-8-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;295 K;0.21 M sodium citrate tribasic dihydrate, 19.09% PEG3350
分辨率 1.84 Å R-free 0.217
8VQ4 CDK2-CyclinE1 in complex with allosteric inhibitor I-125A. 提交 2024-01-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1AC5 (8R)-6-(1-benzyl-1H-pyrazole-4-carbonyl)-N-[(2S,3R)-3-(2-cyclohexylethoxy)-1-(methylamino)-1-oxobutan-2-yl]-2-[(1S)-2,2-dimethylcyclopropane-1-carbonyl]-2,6-diazaspiro[3.4]octane-8-carboxamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;294 K;0.21 M sodium citrate tribasic dihydrate, 19.5% PEG3350
分辨率 1.90 Å R-free 0.219
9BJC Crystal structure of CDK2/Cyclin E1 in complex with XC208 提交 2024-04-25 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa) 片段:residues 96-378
未记录 A1AQZ (5aS,6S,7S)-3,7-dihydroxy-6-methoxy-1,4,6,9-tetramethyl-6,7-dihydrodibenzo[b,f][1,4]oxazepine-8,11(5aH,10H)-dione × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 7.5;298 K;0.1M Tris pH 7.5, 3.6M NaCl
分辨率 2.22 Å R-free 0.213
9D0V Crystal structure of CDK2/CyclinE1 in complex with Cpd 2 提交 2024-08-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
非标准单体:是(mmCIF未提供具体位点) A1A1H 6-chloro-8-cyclopentyl-2-[4-(ethanesulfonyl)-2-methylanilino]pyrido[2,3-d]pyrimidin-7(8H)-one × 1 PEG DI(HYDROXYETHYL)ETHER × 1 GOL GLYCEROL × 3 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1 M Bis-Tris pH 6.5, 3.0 M Sodium Chloride, 25% glycerol.
分辨率 2.54 Å R-free 0.231
9D0W Cryo-EM structure of CDK2/CyclinE1 in complex with CRBN/DDB1 and Cpd 4 提交 2024-08-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 D 96–378(283 aa)
未记录 ZN ZINC ION × 1 A1A1I (3R)-3-(5-{4-[(2-{4-[(8-cyclopentyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]-3-methylbenzene-1-sulfonyl}-7-azaspiro[3.5]nonan-7-yl)methyl]piperidin-1-yl}-4-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)piperidine-2,6-dione × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.95 Å
9D0X Cryo-EM structure of CDK2/CyclinE1 in complex with CRBN/DDB1 and Cpd 4 (local mask) 提交 2024-08-07 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 D 96–378(283 aa)
未记录 ZN ZINC ION × 1 A1A1I (3R)-3-(5-{4-[(2-{4-[(8-cyclopentyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino]-3-methylbenzene-1-sulfonyl}-7-azaspiro[3.5]nonan-7-yl)methyl]piperidin-1-yl}-4-fluoro-3-methyl-2-oxo-2,3-dihydro-1H-1,3-benzimidazol-1-yl)piperidine-2,6-dione × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 2.84 Å
9GOP Crystal structure of CDK2-cyclin E1 bound by compound 30 提交 2024-09-05 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1IOI 2-[(2~{S})-1-[9-ethyl-6-[(2-methyl-5-methylsulfonyl-pyrazol-3-yl)amino]purin-2-yl]-4,4-bis(fluoranyl)pyrrolidin-2-yl]propan-2-ol × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;8-15 % PEG3350, 0.2M Na3Cit pH 8.0
分辨率 2.16 Å R-free 0.271
9GP3 Crystal structure of CDK2-cyclin E1 bound by compound 11 (AZD8421) 提交 2024-09-06 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1IOP (3~{S})-~{N}-ethyl-3-[[9-ethyl-2-[[(2~{R},3~{S})-2-oxidanylpentan-3-yl]amino]purin-6-yl]amino]pyrrolidine-1-sulfonamide × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;8-15% PEG3350 / 0.2M Na3Cit pH8.0
分辨率 2.45 Å R-free 0.273
9NYQ Crystal structure of CDK2/CyclinE1 in complex with Cpd 3 提交 2025-03-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 1–410(410 aa)
未记录 A1B7H 4-({4-[(1s,4s)-4-hydroxy-4-methylcyclohexyl]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-N,3-dimethylbenzene-1-sulfonamide × 1 CIT CITRIC ACID × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.1M Tri-Ammonium citrate, pH7.0,13% PEG3350
分辨率 2.85 Å R-free 0.264
9NYR Cryo-EM structure of CDK2/CyclinE1 in complex with CRBN/DDB1 and Cpd 24 提交 2025-03-28 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 E 96–378(283 aa)
未记录 A1B7G N-{(1R,4S)-4-[(4-{3-chloro-4-[(3R)-2,6-dioxo-1,2,3,6-tetrahydropyridin-3-yl]phenyl}piperazin-1-yl)methyl]cyclohexyl}-4-({4-[(3S)-3-hydroxy-3-methylpiperidin-1-yl]-5-(trifluoromethyl)pyrimidin-2-yl}amino)-3-methylbenzene-1-sulfonamide × 1 ZN ZINC ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.5;50mM HEPES, pH 7.5, 150mM NaCl, 2mM TCEP, 2 mM FFC8, protein = 13.4 mg/ml
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.90 Å
9OB2 CDK2/CyclinE bound to compound 11 with P-loop in the EE and CC conformations 提交 2025-04-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1CAE (1R,3R)-3-(3-{2-[4-(methanesulfonyl)phenyl]acetamido}-1H-pyrazol-5-yl)cyclopentyl (1-methylcyclopropyl)carbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.115 M Sodium Citrate, 15% PEG 3350
分辨率 2.12 Å R-free 0.254
9OB3 CDK2/CyclinE bound to compound 16 with P-loop in the EE conformation 提交 2025-04-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1CAH (1R,3R)-3-{3-[(pyrazine-2-carbonyl)amino]-1H-pyrazol-5-yl}cyclopentyl [(1S)-1-cyclopropylethyl]carbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.115 M Sodium Citrate, 15% PEG 3350
分辨率 1.98 Å R-free 0.244
9OB4 CDK2/CyclinE bound to compound 19 with P-loop in the EE and EC conformations 提交 2025-04-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1CAF (1R,3R)-3-{3-[(cyclohexanecarbonyl)amino]-1H-pyrazol-5-yl}cyclopentyl [(1S)-1-cyclopropylethyl]carbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;P24864
分辨率 1.95 Å R-free 0.251
9OB5 CDK2/CyclinE bound to compound 20 with P-loop in the EE and CC conformations 提交 2025-04-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1CAG (1R,3R)-3-{3-[3-(pyridin-3-yl)propanamido]-1H-pyrazol-5-yl}cyclopentyl (1-methylcyclopropyl)carbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.115 M Sodium Citrate, 15% PEG 3350
分辨率 2.10 Å R-free 0.255
9OB6 CDK2/CyclinE bound to compound 21 with P-loop in the EE and CC conformations 提交 2025-04-22 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 96–378(283 aa)
未记录 A1CAI (1R,3R)-3-{3-[2-(4-methoxyphenyl)acetamido]-1H-pyrazol-5-yl}cyclopentyl propan-2-ylcarbamate × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;0.115 M Sodium Citrate, 15% PEG 3350
分辨率 2.00 Å R-free 0.256